Analytical Data
-
Gene name
TNFRSF21
- Application
-
Alternative Names
TNFRSF21；DR6；Tumor necrosis factor receptor superfamily member 21
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75509
-
Expression Region
42-350aa
-
AA Sequence
QPEQKASNLIGTYRHVDRATGQVLTCDKCPAGTYVSEHCTNTSLRVCSSC PVGTFTRHENGIEKCHDCSQPCPWPMIEKLPCAALTDRECTCPPGMFQSN ATCAPHTVCPVGWGVRKKGTETEDVRCKQCARGTFSDVPSSVMKCKAYTD CLSQNLVVIKPGTKETDNVCGTLPSFSSSTSPSPGTAIFPRPEHMETHEV PSSTYVPKGMNSTESNSSASVRPKVLSSIQEGTVPDNTSSARGKEDVNKT LPNLQVVNHQQGPHHRHILKLLPSMEATGGEKSSTPIKGPKRGHPRQNLH KHFDINEHLVDHHHHHH
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF21, also known as DR6 (Death Receptor 6), is a member of the tumor necrosis factor receptor superfamily that plays a crucial role in various physiological and pathological processes, including cell apoptosis, immune response, and inflammation. Initially identified for its involvement in programmed cell death, TNFRSF21 has garnered significant attention due to its dual role in both promoting and inhibiting apoptosis, depending on the cellular context and receptor interactions. Research has indicated that aberrations in TNFRSF21 signaling pathways are linked to various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Consequently, the development and study of recombinant TNFRSF21 protein have become paramount for elucidating its functional mechanisms and therapeutic potential. By generating recombinant TNFRSF21, researchers aim to investigate its binding partners, downstream signaling pathways, and effects on cellular behavior, as well as explore its potential as a target for novel therapeutic agents. The study of this protein not only enhances our understanding of TNFRSF21's biological roles but also opens up avenues for innovative treatments for diseases associated with its dysregulation.
